Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2017
Same author

Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients.

Journal of pediatric hematology/oncology·2017
Same author

Dendritic cell vaccines: A review of recent developments and their potential pediatric application.

Human vaccines & immunotherapeutics·2016
Same author

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.

Journal of immunology research·2015
Same author

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.

Cancer immunology, immunotherapy : CII·2015
Same author

Targeting cancer-testis antigens in recurrent pediatric brain tumors.

Journal of neuro-oncology·2015

Related Experiment Video

Updated: Mar 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Cancer testis antigen and immunotherapy.

Deepa Kolaseri Krishnadas1, Fanqi Bai1, Kenneth G Lucas1

  • 1Department of Pediatrics, Division of Hematology/Oncology, University of Louisville, KY, USA.

Immunotargets and Therapy
|July 30, 2016
PubMed
Summary

Cancer testis antigens are promising targets for cancer immunotherapy. Vaccines targeting antigens like MAGE-A1, MAGE-A3, and NY-ESO-1 show potential for clinical and immunologic responses in various tumors.

Keywords:
cancer testis antigensimmunotherapyvaccine

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.1K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Related Experiment Videos

Last Updated: Mar 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.1K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Cancer testis (CT) antigens represent a significant advancement in identifying novel targets for cancer immunotherapy.
  • Previous research indicates that CT antigen-based vaccines, including peptide and dendritic cell vaccines, can induce clinical and immunological responses across diverse tumor types.

Purpose of the Study:

  • This review aims to detail the expression patterns of key CT antigens: Melanoma Antigen Family A, 1 (MAGE-A1), Melanoma Antigen Family A, 3 (MAGE-A3), and New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) in various malignancies.
  • The review also aims to present the current understanding and progress in CT antigen-based cancer immunotherapy.

Main Methods:

  • Literature review of studies on CT antigen expression in malignancies.
  • Analysis of existing data on the immunogenicity and clinical efficacy of CT antigen-based vaccines (peptide and dendritic cell).
  • Synthesis of current knowledge on CT antigen-based immunotherapy strategies.

Main Results:

  • CT antigens, including MAGE-A1, MAGE-A3, and NY-ESO-1, are expressed in a range of human cancers.
  • CT antigen vaccines have demonstrated the ability to elicit both clinical and immunological responses in patients with different types of tumors.
  • The expression profiles of these antigens vary across different malignancies, influencing therapeutic strategies.

Conclusions:

  • CT antigens are validated targets for cancer immunotherapy due to their tumor-specific expression and immunogenicity.
  • CT antigen-based vaccines hold significant promise for the treatment of various cancers, warranting further clinical investigation.
  • Understanding the expression of MAGE-A1, MAGE-A3, and NY-ESO-1 is crucial for developing effective CT antigen-based immunotherapies.